Nu-Med Plus (NUMD) EBIT Growth (3y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.70% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 7.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.83% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 75.54% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -2.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -24.91% |
| 10 | Nu-Med Plus | - | - | - | -15.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.14% |
| Sep 30, 2025 | 44.22% |
| Jun 30, 2025 | 43.60% |
| Mar 31, 2025 | 32.07% |
| Dec 31, 2024 | 56.43% |
| Sep 30, 2024 | 47.21% |
| Jun 30, 2024 | 60.07% |
| Mar 31, 2024 | 61.36% |
| Dec 31, 2023 | 52.16% |
| Sep 30, 2023 | 67.71% |
| Jun 30, 2023 | 70.61% |
| Mar 31, 2023 | 43.47% |
| Dec 31, 2022 | 68.56% |
| Sep 30, 2022 | 26.50% |
| Jun 30, 2022 | 38.01% |
| Mar 31, 2022 | 47.98% |
| Dec 31, 2021 | 31.88% |
| Sep 30, 2021 | 39.02% |
| Jun 30, 2021 | -14.31% |
| Mar 31, 2021 | -35.76% |
| Dec 31, 2020 | -28.66% |
| Sep 30, 2020 | -48.35% |
| Jun 30, 2020 | -101.34% |
| Mar 31, 2020 | -28.89% |
| Dec 31, 2019 | -30.43% |
| Sep 30, 2019 | 40.55% |
| Jun 30, 2019 | -11.06% |
| Mar 31, 2019 | -86.18% |
| Dec 31, 2018 | -34.59% |
| Sep 30, 2018 | -19.84% |
| Jun 30, 2018 | 24.32% |
| Mar 31, 2018 | -6.30% |
| Dec 31, 2017 | 110.69% |
| Sep 30, 2017 | 16.77% |
| Jun 30, 2017 | 17.51% |
| Mar 31, 2017 | 26.97% |
| Sep 30, 2016 | -99.42% |
| Jun 30, 2016 | -73.79% |
| Mar 31, 2016 | 6.57% |
| Dec 31, 2015 | 72.11% |
| Mar 31, 2015 | -82.44% |